Details

Autor(en) / Beteiligte

• Holloway, Robert G
• Shoulson, Ira
• Fahn, Stanley
• Kieburtz, Karl
• Lang, Anthony
• Marek, Kenneth
• McDermott, Michael
• Seibyl, John
• Weiner, William
• Musch, Bruno
• Kamp, Cornelia
• Welsh, Mickie
• Shinaman, Aileen
• Pahwa, Rajesh
• Barclay, Lynn
• Hubble, Jean
• LeWitt, Peter
• Miyasaki, Janis
• Suchowersky, Oksana
• Stacy, Mark
• Russell, David S
• Ford, Blair
• Hammerstad, John
• Riley, David
• Standaert, David
• Wooten, Frederick
• Factor, Stewart
• Jankovic, Joseph
• Atassi, Farah
• Kurlan, Roger
• Panisset, Michel
• Rajput, Ali
• Rodnitzky, Robert
• Shults, Cliff
• Petsinger, Giselle
• Waters, Cheryl
• Pfeiffer, Ronald
• Biglan, Kevin
• Borchert, Leona
• Montgomery, Amy
• Sutherland, Laura
• Weeks, Carolyn
• DeAngelis, Maryan
• Sime, Elspeth
• Wood, Susan
• Pantella, Carol
• Harrigan, Mary
• Fussell, Barbara
• Dillon, Sandra
• Alexander-Brown, Barbara
• Rainey, Pamela
• Tennis, Marsha
• Rost-Ruffner, Elke
• Brown, Diane
• Evans, Sharon
• Berry, Debra
• Hall, Jean
• Shirley, Theresa
• Dobson, Judith
• Fontaine, Deborah
• Pfeiffer, Brenda
• Brocht, Alicia
• Bennett, Susan
• Daigneault, Susan
• Hodgeman, Karen
• O'Connell, Carolynn
• Ross, Tori
• Richard, Karen
• Watts, Arthur

Titel

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

Ist Teil von

• Archives of neurology (Chicago), 2004-07, Vol.61 (7), p.1044

Ort / Verlag

United States

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes. Multicenter, parallel-group, double-blind, randomized controlled trial. Academic movement disorders clinics at 22 sites in the United States and Canada. Patients with early Parkinson disease (N = 301) who required dopaminergic therapy to treat emerging disability, enrolled between October 1996 and August 1997 and observed until August 2001. Subjects were randomly assigned to receive 0.5 mg of pramipexole 3 times per day with levodopa placebo (n = 151) or 25/100 mg of carbidopa/levodopa 3 times per day with pramipexole placebo (n = 150). Dosage was escalated during the first 10 weeks for patients with ongoing disability. Thereafter, investigators were permitted to add open-label levodopa or other antiparkinsonian medications to treat ongoing or emerging disability. Time to the first occurrence of dopaminergic complications: wearing off, dyskinesias, on-off fluctuations, and freezing; changes in the Unified Parkinson's Disease Rating Scale and quality-of-life scales; and adverse events. Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02). Initial levodopa treatment resulted in a significant reduction in the risk of freezing (25.3% vs 37.1%; hazard ratio, 1.7; 95% CI, 1.11-2.59; P =.01). By 48 months, the occurrence of disabling dyskinesias was uncommon and did not significantly differ between the 2 groups. The mean improvement in the total Unified Parkinson's Disease Rating Scale score from baseline to 48 months was greater in the levodopa group than in the pramipexole group (2 +/- 15.4 points vs -3.2 +/- 17.3 points, P =.003). Somnolence (36% vs 21%, P =.005) and edema (42% vs 15%, P<.001) were more common in pramipexole-treated subjects than in levodopa-treated subjects. Mean changes in quality-of-life scores did not differ between the groups. Initial treatment with pramipexole resulted in lower incidences of dyskinesias and wearing off compared with initial treatment with levodopa. Initial treatment with levodopa resulted in lower incidences of freezing, somnolence, and edema and provided for better symptomatic control, as measured by the Unified Parkinson's Disease Rating Scale, compared with initial treatment with pramipexole. Both options resulted in similar quality of life. Levodopa and pramipexole both appear to be reasonable options as initial dopaminergic therapy for Parkinson disease, but they are associated with different efficacy and adverse-effect profiles.